Clinical Trials Logo

B-Cell Lymphomas clinical trials

View clinical trials related to B-Cell Lymphomas.

Filter by:

NCT ID: NCT01613300 Completed - B-Cell Lymphomas Clinical Trials

Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients

Start date: April 4, 2012
Phase: Phase 2
Study type: Interventional

The aim of this study is rate of acute graft-versus-host disease II-IV measured at day +365according to conventional criteria (Przepiorka et al. 1995) in patients with high risk non-Hodgkin lymphoma B subjects with Allogeneic Stem Cell Transplant

NCT ID: NCT01478269 Completed - B-Cell Lymphomas Clinical Trials

Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen

ProDLBCL
Start date: May 2009
Phase: N/A
Study type: Observational

This study is a retrospective analysis of an homogeneous population of patients with aggressive B-cell lymphoma and treated upfront with R-CHOP or R-CHOP like regimens to reassess the prognostic factors and hopefully to identify more accurate prognostic subgroups with a clinical and therapeutical relevance.

NCT ID: NCT01068392 Completed - B-cell Lymphomas Clinical Trials

Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL)

Start date: October 2009
Phase: Phase 2
Study type: Interventional

The investigators are willing to investigate the efficacy and safety of oxaliplatin and prednisolone (Ox-P) combination in patients with previously treated MZL who have a few clinical trial data.

NCT ID: NCT00801216 Recruiting - B-Cell Lymphomas Clinical Trials

High-Dose Sequential Chemoimmunotherapy for B-Cell Lymphomas With Central Nervous System Involvement

SCNSL1
Start date: January 2007
Phase: Phase 2
Study type: Interventional

This prospective trial will assess the activity and feasibility of a new high-dose methotrexate-based high-dose sequential chemotherapy combination in patients with B-cell lymphomas and CNS involvement at diagnosis or relapse. Selected drugs, with a well-documented anti-lymphoma activity, will be administered at high doses to increase blood-brain barrier penetration and CNS bioavailability as well as to reduce potential cross-resistance.